CN102552994A - Medical slow release material and preparation method thereof - Google Patents
Medical slow release material and preparation method thereof Download PDFInfo
- Publication number
- CN102552994A CN102552994A CN2011104588108A CN201110458810A CN102552994A CN 102552994 A CN102552994 A CN 102552994A CN 2011104588108 A CN2011104588108 A CN 2011104588108A CN 201110458810 A CN201110458810 A CN 201110458810A CN 102552994 A CN102552994 A CN 102552994A
- Authority
- CN
- China
- Prior art keywords
- microsphere
- weeks
- medicine
- slow release
- temperature sensitive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000463 material Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 239000004005 microsphere Substances 0.000 claims abstract description 155
- 239000003814 drug Substances 0.000 claims abstract description 56
- 239000000243 solution Substances 0.000 claims abstract description 34
- 229920000642 polymer Polymers 0.000 claims abstract description 24
- 239000011259 mixed solution Substances 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 229920001577 copolymer Polymers 0.000 claims description 27
- 238000013268 sustained release Methods 0.000 claims description 22
- 239000012730 sustained-release form Substances 0.000 claims description 22
- 239000002994 raw material Substances 0.000 claims description 18
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 17
- 230000000844 anti-bacterial effect Effects 0.000 claims description 13
- 102000013275 Somatomedins Human genes 0.000 claims description 12
- 229940088710 antibiotic agent Drugs 0.000 claims description 12
- 229920000954 Polyglycolide Polymers 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 claims description 9
- 239000004633 polyglycolic acid Substances 0.000 claims description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 8
- 239000004626 polylactic acid Substances 0.000 claims description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 8
- 238000005516 engineering process Methods 0.000 claims description 7
- 229930182566 Gentamicin Natural products 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 5
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 5
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 5
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 5
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 5
- 108010059993 Vancomycin Proteins 0.000 claims description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
- 229960003165 vancomycin Drugs 0.000 claims description 5
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 5
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 5
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 claims description 4
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 claims description 4
- 229930193140 Neomycin Natural products 0.000 claims description 4
- 239000004100 Oxytetracycline Substances 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 4
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 claims description 4
- 239000004098 Tetracycline Substances 0.000 claims description 4
- 108700029371 albomycin Proteins 0.000 claims description 4
- 229960003022 amoxicillin Drugs 0.000 claims description 4
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 4
- 229960004099 azithromycin Drugs 0.000 claims description 4
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 4
- 229960002588 cefradine Drugs 0.000 claims description 4
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 claims description 4
- 229960003276 erythromycin Drugs 0.000 claims description 4
- 229960000318 kanamycin Drugs 0.000 claims description 4
- 229930027917 kanamycin Natural products 0.000 claims description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 4
- 229930182823 kanamycin A Natural products 0.000 claims description 4
- 229960000282 metronidazole Drugs 0.000 claims description 4
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 4
- 229960004927 neomycin Drugs 0.000 claims description 4
- 229960000625 oxytetracycline Drugs 0.000 claims description 4
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 4
- 235000019366 oxytetracycline Nutrition 0.000 claims description 4
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 4
- 229940049954 penicillin Drugs 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 229960003485 ribostamycin Drugs 0.000 claims description 4
- 229930190553 ribostamycin Natural products 0.000 claims description 4
- NSKGQURZWSPSBC-NLZFXWNVSA-N ribostamycin Chemical compound N[C@H]1[C@H](O)[C@@H](O)[C@H](CN)O[C@@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](CO)O2)O)[C@H](O)[C@@H](N)C[C@H]1N NSKGQURZWSPSBC-NLZFXWNVSA-N 0.000 claims description 4
- NSKGQURZWSPSBC-UHFFFAOYSA-N ribostamycin A Natural products NC1C(O)C(O)C(CN)OC1OC1C(OC2C(C(O)C(CO)O2)O)C(O)C(N)CC1N NSKGQURZWSPSBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- ZPCCSZFPOXBNDL-RSMXASMKSA-N spiramycin II Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]([C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)OC(C)=O)[C@H]1CC[C@H](N(C)C)[C@H](C)O1 ZPCCSZFPOXBNDL-RSMXASMKSA-N 0.000 claims description 4
- 229950006796 spiramycin ii Drugs 0.000 claims description 4
- 229960005322 streptomycin Drugs 0.000 claims description 4
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 4
- 229960002180 tetracycline Drugs 0.000 claims description 4
- 229930101283 tetracycline Natural products 0.000 claims description 4
- 235000019364 tetracycline Nutrition 0.000 claims description 4
- 150000003522 tetracyclines Chemical class 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 239000006199 nebulizer Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 6
- 210000000988 bone and bone Anatomy 0.000 description 34
- 238000000034 method Methods 0.000 description 13
- 239000000499 gel Substances 0.000 description 7
- 230000036760 body temperature Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 3
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002324 minimally invasive surgery Methods 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229910000497 Amalgam Inorganic materials 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000006735 Periostitis Diseases 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 239000011557 critical solution Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000003460 periosteum Anatomy 0.000 description 2
- 230000001543 purgative effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010056377 Bone tuberculosis Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000007875 Femur Head Necrosis Diseases 0.000 description 1
- 208000009360 Osteoarticular Tuberculosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical class O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 238000009418 renovation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Abstract
The invention relates to an injectable medical slow release material which is mainly formed by the mixing of pulse type releasing microspheres carrying drugs and a temperature sensitive polymer solution. The preparation method mainly comprises the steps of preparing the pulse type releasing microspheres carrying drugs; preparing the temperature sensitive polymer solution; and mixing the pulse type releasing microspheres carrying drugs with the temperature sensitive polymer solution, and stirring the mixture to be uniform to form a mixed solution. According to the invention, carrying factors or microspheres of drugs are uniformly dispersed in the solution of the temperature sensitive injectable carrier, and after the solution is injected to a treatment position, the material is solidified quickly and then degrades slowly to release drugs or factors, so as to prolong the active time of the factors in the body, and improve the controllability on factor release speed and factor release cycle, thereby realizing the combination of release of same or different drugs in desired locations and different time slots alternatively and the manner of minimally invasive treatments.
Description
Technical field
The invention belongs to the bioactive materials field, refer in particular to injectable sustained-release material and preparation and method for using that a kind of temperature sensitive type carries microsphere.
Background technology
In China; Annual cause the patient of bone injury to reach 300 ~ 4,000,000 person-times because of vehicle accident and production safety accident; Add orthopaedic diseases such as bone tumor, bone tuberculosis, ischemic necrosis of femoral head; Caused the damaged patient of numerous bones, therefore, damaged a kind of serious disease and the social problem that influences the health of people life that become of bone.Perfect along with the raising of the aging of China's population, health of people consciousness and the consuming capacity and national medical system, the bone renovating material market demand of China sharply increases.From the body bone is ideal bone impairment renovation material, has increased new wound and the misery of patient but get the bone process, and originate limited, be difficult for mouldingly, be difficult to satisfy the requirement that big section bone is transplanted, more be unwell to juvenile patient; And there are the risk of immunological rejection, propagation source of disease and initiation operation sequela in allograph bone and bone xenograft, add the restriction of donor source, and the obstacle of medical ethics aspect, have limited it and have used clinically.
In order to satisfy clinical demand, in the last few years, the existing synthetic bone reparing biological material of kinds of artificial obtained extensive use clinically, and wherein the injectable bone repair materials is wherein most important one type.At first, the injectable bone repair materials can implant through the mode of injection, wound is little, has eliminated the relevant many complication of traditional bone transplant operation; Secondly, this bone material possesses good plasticity, the timbering material of the porous microstructure of in-situ solidifying, and formation in vivo, performance bone conduction effect; At last, material is slowly degraded in the back that implants, and is followed growing into of the new bone of host.In the last few years, along with the development of less invasive techniques, the injection aquagel material received people's attention gradually, its research and use increasingly extensive.Injection aquagel is strong except possessing plasticity, can fill various difform damaged and in-situ solidifyings, and the wound that causes is little; Can reduce outside patient's the advantages such as misery; Hydrogel is the bionical characteristic of type of possessing extracellular matrix also, and the three-dimensional aquation network structure of height helps the migration and the growth of cell in tissue regeneration and the wound healing process; The curing molding mild condition is particularly suitable for the carrier as protein and cell.Wherein, More and more receive the attention of researcher through the injectable type gel of temperature sensitive type phase transformation molding; Especially lower critical solution temperature (Lower Critical Solution Temperature, LCST) a little less than the hydrogel of body temperature, main cause is that this gellike is at room temperature for liquid; Under body temperature, just can solidify rapidly, condition of cure and simple to operate, be very suitable for being written into of cell or protein factor.
In the process of various orthopaedic disease treatments, need be used some medicines or the factor, but these medicines or factor half-life are short, very fast diluted and metabolism during topical application, its bioavailability is extremely low; Especially the medicine of protides such as some somatomedin, hormone, production cost is expensive, lets patient be difficult to bear, and has restricted the market expansion and the application of this series products.But prior art can't provide efficiently at present, the slow-released system of safety, Wicresoft.
Summary of the invention
Technical problem to be solved by this invention is: provide a kind of temperature sensitive type of Minimally Invasive Surgery that is applicable to carry the injectable sustained-release material of microsphere, to solve the technical barrier that in the prior art a spot of pharmaceutical agent is carried out safe and effective release.
For solving the problems of the technologies described above, the present invention adopts following technical scheme: a kind of medical slow release material mainly is to be mixed in the mixture that forms in the temperature sensitive type polymer solution by sustained-release micro-spheres; Said sustained-release micro-spheres is loaded with medicine, and forms the alternately microsphere of the pulsed slow release of release of identical or different medicine by the microsphere of different deenergized periods according to certain mixed together.
The mass concentration scope of said temperature sensitive type poly compound solution chamber relaxing the bowels with purgatives of warm nature is 1 ~ 20%, and this solution forms solid gel in the internal energy rapid curing of 31 ~ 36 ℃ scope; Said sustained-release micro-spheres mass and size specific concentration in amalgam is 0.01 ~ 10%.Preferably, said temperature sensitive type polymer solution is to be formed to dissolving fully by normal saline or phosphate buffer dissolving temperature sensitive type poly compound.Said temperature sensitive type poly compound is preferable over a kind of in poly-N-isopropyl acrylamide PNIPAAm, the grafted Polyethylene Glycol of PNIPAAm (PNIPAAm-g-PEG), the grafted chitosan of PNIPAAm (PNIPAAm-g-Ch), the grafted collagen of PNIPAAm (PNIPAAm-g-Col), the grafted hyaluronic acid of PNIPAAm (PNIPAAm-g-HA), the grafted chondroitin sulfate of PNIPAAm (PNIPAAm-g-CS), the grafted sodium alginate of the PNIPAAm temperature sensitive type polymer such as (PNIPAAm-g-Alg) and several kinds, and the molecular weight ranges of these polymer is at 5 ~ 50KDa.
Contained medicine is antibacterials and/or somatomedin; The content of medicine in microsphere accounts for 0.001 ~ 5% of microsphere gross mass; Said sustained-release micro-spheres mass and size specific concentration in mixture is 0.01 ~ 10%.Said antibacterials are selected from one or more in streptomycin, cefradine, gentamycin, acetylspiramycin, erythromycin, albomycin, amoxicillin, oxytetracycline, kanamycin, penicillin, metronidazole, danshensu, neomycin, ribostamycin, tetracycline, vancomycin, the azithromycin.Said somatomedin is selected from one or more in rhBMP-2, rhBMP-7, insulin-like growth factor-i, transforming growth factor-beta, VEGF, basic fibroblast growth factor, platelet derived growth factor or the active polypeptide etc.
Said microsphere raw material is selected from one or more in polylactic acid, polyglycolic acid or the lactic acid-ethanol copolymer, and contains lactic acid-ethanol copolymer at least; The molecular weight ranges of microsphere raw material is 1~200KDa.The lactic acid-ethanol copolymer molecular weight is 1 ~ 3KDa in microsphere, and accounts for the microsphere gross mass and reach 30% when above, and microsphere can be regulated in 1 ~ 2 week deenergized period.When the lactic acid-ethanol copolymer molecular weight greater than 3 KDa and less than 10KDa, and account for the microsphere gross mass and reach more than 50%, can regulate in 3 ~ 6 weeks deenergized period.When the lactic acid-ethanol copolymer molecular weight greater than 10KDa and less than 200 KDa, and the gross mass that accounts for microsphere is less than 50%, can regulate in 7 ~ 12 weeks deenergized period.
Said pulsed discharges microsphere and comprises that be 5 kinds of microspheres in 1 week, 2 weeks, 4 weeks, 8 weeks and 12 weeks deenergized period, and mass ratio is (1 ~ 10): (1 ~ 10): (1 ~ 10): (1 ~ 10): (1 ~ 10); Be that the contained medicine of microsphere in 1 week and 2 weeks is antibacterials deenergized period; Be that the contained medicine of microsphere in 4 weeks, 8 weeks and 12 weeks is a somatomedin deenergized period.
Medical slow release material of the present invention, it is an injection type.
Medical slow release preparation methods of the present invention may further comprise the steps:
1) pulsed of preparation medicine carrying thing discharges microsphere;
2) preparation temperature sensitive type polymer solution;
3) mixing: the medicine carrying pulsed of step 1) preparation is discharged microsphere and step 2) solution of preparation mixes, stirs, prepares the mixed solution of microsphere and polymer.
Further comprise step 4): solidifying, specifically is that the mixed solution of step 3 preparation is packed in the syringe, is expelled to therapentic part, and solidifies rapidly.
The technology of this step 1) further comprises:
At first with difference microsphere raw material and the said medicine difference wiring solution-forming of deenergized periods; Wherein the microsphere raw material is selected from one or more in polylactic acid, polyglycolic acid or the lactic acid-ethanol copolymer; And contain lactic acid-ethanol copolymer at least, the molecular weight ranges of microsphere raw material is 1~200KDa;
Produce the microsphere drop through the nebulizer atomizing; Obtain the different microsphere that is loaded with medicine deenergized period behind the volatile dry respectively: wherein; When the lactic acid-ethanol copolymer molecular weight is 1 ~ 3KDa, and accounts for the microsphere gross mass and reach 30% when above, obtain the microsphere that to regulate in 1 ~ 2 week deenergized period; When the lactic acid-ethanol copolymer molecular weight greater than 3 KDa and less than 10KDa, and account for the microsphere gross mass and reach more than 50%, obtain the microspheres that can regulate in 3 ~ 6 weeks deenergized period; When the lactic acid-ethanol copolymer molecular weight greater than 10KDa and less than 200KDa, and the gross mass that accounts for microsphere is less than 50%, obtains the microsphere that deenergized period can adjusting in 7 ~ 12 weeks;
Then, with the microspheres of different deenergized periods together, can form the microsphere of the pulsed slow release that identical or different medicine alternately discharges according to certain mixed.
Beneficial effect of the present invention is following: the present invention is on the basis of sustained-release micro-spheres and temperature sensitive type injectable gel, and a kind of temperature sensitive type of Minimally Invasive Surgery that is applicable to that makes carries the injectable sustained-release material of microsphere.It has pulse slow-releasing function, can realize the sustained release of different pharmaceutical in different time sections; Plasticity is good, degradable, can promote characteristics such as the damaged regeneration of bone, good stability, safety height.The shape and size bone that can be used for filling various complicacy is damaged, and the solidification temperature of material is in a liquid state under the room temperature between 31 ~ 36 ℃, can be at self-curing under the body temperature, and hardening time was at 3 ~ 15 minutes; Can keep due shape in defect repair in cycle, possess excellent biological compatibility simultaneously, can promote the regeneration of bone.
Further; The microsphere that the present invention will be carried the factor or medicine is dispersed in the solution of temperature sensitive type injectable carrier uniformly, be expelled to therapentic part after, material solidifies rapidly; Slowly degraded discharges the medicine or the factor then; With the elongation factor active time in vivo, improve factor rate of release and the controllability of deenergized period, realized identical or different medicine in the precalculated position, the alternately combination of release and minimally-invasive treatment means of different time sections.
The specific embodiment
In the process of various orthopaedic disease treatments, some medicines or the factor (like hBMP-2 or-7, i.e. rhBMP-2 or rhBMP-7) are very favourable to bone reparative regeneration and antibacterial therapy.
And microsphere is a kind of good slow release carrier, if can the degraded through microsphere of medicine or the factor progressively be discharged the safe and effective input that just can realize the medicine or the factor.But microsphere is difficult to be fixed on therapentic part, runs off easily and moves, and therefore also needs other materials to make it be fixed on therapentic part as carrier.In addition, microsphere is in case degraded is broken, and the medicine or the factor will discharge rapidly.
The present invention provides a kind of medical slow release material, mainly is to be mixed in the mixture that forms in the temperature sensitive type polymer solution by sustained-release micro-spheres.Said sustained-release micro-spheres is loaded with medicine, and forms the alternately microsphere of the pulsed slow release of release of identical or different medicine by the microsphere of different deenergized periods according to certain mixed together.The microsphere mixed proportion of different deenergized periods can be regulated and selects according to concrete needs, and for example, the mass ratio that the microsphere of different deenergized periods mixes each other is (1 ~ 10): (1 ~ 10).
The mass concentration scope of said temperature sensitive type poly compound solution chamber relaxing the bowels with purgatives of warm nature is 1 ~ 20%, and this solution forms solid gel in the internal energy rapid curing of 31 ~ 36 ℃ scope; Said sustained-release micro-spheres mass and size specific concentration in amalgam is 0.01 ~ 10%.Preferably, said temperature sensitive type polymer solution is to be formed to dissolving fully by normal saline or phosphate buffer dissolving temperature sensitive type poly compound.
Contained medicine is antibacterials and/or somatomedin; The content of medicine in microsphere accounts for 0.001 ~ 5% of microsphere gross mass; Said sustained-release micro-spheres mass and size specific concentration in mixture is 0.01 ~ 10%.Said antibacterials are selected from one or more in streptomycin, cefradine, gentamycin, acetylspiramycin, erythromycin, albomycin, amoxicillin, oxytetracycline, kanamycin, penicillin, metronidazole, danshensu, neomycin, ribostamycin, tetracycline, vancomycin, the azithromycin.Said somatomedin is selected from one or more in rhBMP-2, rhBMP-7, insulin-like growth factor-i, transforming growth factor-beta, VEGF, basic fibroblast growth factor, platelet derived growth factor or the active polypeptide etc.
Said microsphere raw material is selected from one or more in polylactic acid, polyglycolic acid or the lactic acid-ethanol copolymer, and contains lactic acid-ethanol copolymer at least; The molecular weight ranges of microsphere raw material is 1~200KDa.The lactic acid-ethanol copolymer molecular weight is 1 ~ 3 KDa in microsphere, and accounts for the microsphere gross mass and reach 30% when above, and microsphere can be regulated in 1 ~ 2 week deenergized period.When the lactic acid-ethanol copolymer molecular weight greater than 3KDa and less than 10KDa, and account for the microsphere gross mass and reach more than 50%, can regulate in 3 ~ 6 weeks deenergized period.When the lactic acid-ethanol copolymer molecular weight greater than 10KDa and less than 200KDa, and the gross mass that accounts for microsphere is less than 50%, can regulate in 7 ~ 12 weeks deenergized period.
The present invention combines the technology of preparing of temperature sensitive type injectable gel with the pulsed sustained-release micro-spheres, at first prepares the microsphere of pulsed slow release, with microsphere and pulsed microspheres solution mix homogeneously; The microsphere that is about to year factor or medicine is dispersed in the solution of temperature sensitive type injectable carrier uniformly; After being expelled to therapentic part, material solidifies rapidly, and slowly degraded discharges the medicine or the factor then; With elongation factor action time in vivo, improve factor rate of release and the controllability of deenergized period.
Temperature sensitive type of the present invention carries the injectable medical slow release preparation methods of microsphere, specifically mainly may further comprise the steps:
1) microsphere of preparation pulsed slow release ": prepare the different microsphere that is loaded with the medicine or factor deenergized period earlier; with the microspheres of different deenergized periods together, can form " microsphere of pulsed slow release " that identical or different medicine alternately discharges then according to certain mixed;
2) preparation temperature sensitive type polymer solution: at room temperature, adopt normal saline or phosphate buffer dissolving temperature sensitive type poly compound to dissolving fully;
3) mix: the mixed solution that " microsphere of pulsed slow release " and the solution of step 2 preparation of step 1 preparation is mixed, stirs, prepares microsphere and polymer.
This method for preparing can comprise step 4 further: solidifying, specifically is the mixed solution of step 3 preparation is packed in the syringe (syringe can clinical as required needs be designed to different syringe needles); Be expelled to therapentic part, also solidify rapidly.
In said the 1st step, according to the disclosed preparation bone growth factor-carrying microspheres technology of Chinese patent publication number CN101816634A.The microsphere raw material is selected from: polylactic acid (PLA), polyglycolic acid (PGA) or lactic acid-ethanol copolymer (PLGA).With microsphere raw material and some antibacterials or factor wiring solution-forming, produce the microsphere drop through the nebulizer atomizing, volatile dry obtains solid-state-microspherical.The method that medicine adds is identical with the method that protein factor adds.But, the molecular weight and the proportion of raw materials of polylactic acid (PLA), polyglycolic acid (PGA), lactic acid-ethanol copolymer (PLGA) in the microsphere raw material are adjusted and controlled in order to prepare the microsphere of different deenergized periods.At first, the molecular weight range of choice is 1~200KDa, and every kind of microsphere all contains PLGA raw material at least.When the PLGA molecular weight less than 3 KDa, and account for the microsphere gross mass and reach more than 30%, can regulate in 1 ~ 2 week deenergized period; When the PLGA molecular weight greater than 3KDa and less than 10 KDa, and account for the microsphere gross mass and reach more than 50%, can regulate in 3 ~ 6 weeks deenergized period; When the PLGA molecular weight greater than 10KDa and less than 200KDa, and account for the microsphere gross mass less than 50%, can regulate in 7 ~ 12 weeks deenergized period.More specifically, for example, be that the microsphere proportioning raw materials in 1 week is exactly that to adopt molecular weight be that PLGA and the molecular weight of 2 KDa is the PLA of 10KDa deenergized period, and PLGA quality branch accounts for 60% of microsphere gross mass, and the microsphere of preparing as stated above its deenergized period was 1 week.In like manner, according to said method can prepare the microsphere of various different deenergized periods respectively.
In specific embodiment, " pulsed release microsphere " is made up of 5 kinds of microspheres that are 1 week, 2 weeks, 4 weeks, 8 weeks and 12 weeks deenergized period, and mass ratio is (1 ~ 10): (1 ~ 10): (1 ~ 10): (1 ~ 10): (1 ~ 10); And medicine contained in the microsphere can be selected according to actual needs, and drug main will be selected from one of antibacterials and somatomedin the two or the two, and the content in microsphere accounts for 0.001 ~ 5% of microsphere gross mass.Antibacterials mainly are selected from one or more in streptomycin, cefradine, gentamycin, acetylspiramycin, erythromycin, albomycin, amoxicillin, oxytetracycline, kanamycin, penicillin, metronidazole, danshensu, neomycin, ribostamycin, tetracycline, vancomycin, the azithromycin.Somatomedin is selected from one or more in rhBMP-2, rhBMP-7, insulin-like growth factor-i (IGF-1), transforming growth factor-beta (TGF-β), VEGF (VEGF), basic fibroblast growth factor (bFGF), platelet derived growth factor (PDGF) or the active polypeptide etc.Be appreciated that the contained medicine of microsphere also can be according to concrete needs, select other medicine or factor of being suitable for, and be not limited to carry antibacterials and somatomedin.
In said the 2nd step; The temperature sensitive type poly compound is selected from a kind of in poly-N-isopropyl acrylamide (PNIPAAm), the grafted Polyethylene Glycol of PNIPAAm (PNIPAAm-g-PEG), the grafted chitosan of PNIPAAm (PNIPAAm-g-Ch), the grafted collagen of PNIPAAm (PNIPAAm-g-Col), the grafted hyaluronic acid of PNIPAAm (PNIPAAm-g-HA), the grafted chondroitin sulfate of PNIPAAm (PNIPAAm-g-CS), the grafted sodium alginate of the PNIPAAm temperature sensitive type polymer such as (PNIPAAm-g-Alg) and several kinds; The scope of the molecular weight of these polymer is at 5 ~ 50KDa; Mass volume ratio concentration range at the temperature sensitive type polymer solution under the room temperature is 1 ~ 20% (W/V); Its aqueous solution solidifies rapidly in 31 ~ 36 ℃ scope, forms solid gel.
In said the 3rd step, " pulsed release microsphere " mass volume ratio concentration range in solution is 0.01 ~ 10% (W/V).
In the described step 4,, the material direct injection fills and the damaged filling of various irregular bone but being used for the formed cavity of osteoporosis; When material is used for Subperiosteum ossification, need the certain normal saline of injection that the periosteum and the cortical bone of predetermined position are peeled off, inject this material then, when this method was used to raise alveolar bone bone amount, with respect to traditional bone grafting operation, wound was little, cost is low.
The microsphere that the present invention will be carried the factor or medicine is dispersed in the solution of temperature sensitive type injectable carrier uniformly; After being expelled to therapentic part; Material solidifies rapidly, and slowly degraded discharges the medicine or the factor then, with the elongation factor active time in vivo; Improve factor rate of release and the controllability of deenergized period, realized identical or different medicine in the precalculated position, the alternately combination of release and minimally-invasive treatment means of different time sections.
Further specify bone renovating material of the present invention below in conjunction with embodiment, but not as restriction of the present invention.
Embodiment 1
Temperature sensitive type carries the preparation and the method for using of the injectable sustained-release material of microsphere, specifically may further comprise the steps:
1) prepares 5 kinds of microspheres that be 1 week, 2 weeks, 4 weeks, 8 weeks and 12 weeks deenergized period; Then respectively together with the mixed of 1:1:1:1:1; Form " microsphere of pulsed slow release " that alternately discharge; Be that the contained medicine of microsphere in 1 week and 2 weeks is gentamycins deenergized period, accounts for 3% of microsphere gross mass, can play the effect of anti-inflammation in wound site; Be 3 kinds of contained pharmaceutical agent rhBMP-2 of microsphere in 4 weeks, 8 weeks and 12 weeks deenergized period, accounts for 0.005% of microsphere gross mass.
2) at room temperature, adopt phosphate buffer dissolving PNIPAAm-g-Ch,, prepare 5% PNIPAAm-g-Ch solution to dissolving fully;
3) " microsphere of pulsed slow release " of step 1 preparation and the solution that step 2 prepares are mixed, stir, prepare the mixed solution of microsphere and polymer, wherein the content of microsphere is 1% (W/V);
4) mixed solution of step 3 preparation is packed in the syringe by (syringe needle that syringe can be suitable for according to clinical needs design);
5) be expelled to predetermined therapentic part, can solidify rapidly.
Embodiment 2
Temperature sensitive type carries the preparation and the method for using of the injectable sustained-release material of microsphere, specifically may further comprise the steps:
1) prepares 5 kinds of microspheres that be 1 week, 2 weeks, 4 weeks, 8 weeks and 12 weeks deenergized period; Then respectively together with the mixed of 2:1:1:1:1; Form " microsphere of pulsed slow release " that alternately discharge; Be that the contained medicine of microsphere in 1 week and 2 weeks is respectively vancomycin and gentamycin deenergized period, accounts for 3% of microsphere gross mass respectively, can play the effect of anti-inflammation at the damaged severe infections of bone position; Be 3 kinds of contained pharmaceutical agent rhBMP-2 of microsphere in 4 weeks, 8 weeks and 12 weeks deenergized period, accounts for 0.008% of microsphere gross mass.
2) at room temperature, adopt phosphate buffer dissolving PNIPAAm-g-HA,, prepare 10% PNIPAAm-g-HA solution to dissolving fully;
3) " microsphere of pulsed slow release " of step 1 preparation and the solution that step 2 prepares are mixed, stir, prepare the mixed solution of microsphere and polymer, wherein the content of microsphere is 0.8% (W/V);
4) mixed solution of step 3 preparation is packed in the syringe (syringe also can the clinical as required syringe needle that needs design special);
5) be expelled to predetermined therapentic part, can solidify rapidly.
The material that above-mentioned embodiment is prepared is used for alveolar bone when raising, and can carefully be expelled to subperiosteum with biological saline earlier, and periosteum and cortical bone are peeled off; Form certain clearance; Inject material into this position then, material can solidify rapidly under the body temperature effect, after 2 months; The bone of alveolar bone increases, and raises 2 ~ 3mm.When this material is used for the damaged filling of irregular bone, be injected directly into damaged in, can be with whole damaged filling, material can solidify rapidly under the body temperature effect, promotes the damaged reparation of bone.
In a word, above instance utilizes sustained-release micro-spheres and temperature sensitive type injectable gel technology, and a kind of temperature sensitive type of Minimally Invasive Surgery that is applicable to that makes carries the injectable sustained-release material of microsphere.It has pulse slow-releasing function, can realize the sustained release of different pharmaceutical in different time sections; Plasticity is good, degradable, can promote characteristics such as the damaged regeneration of bone, good stability, safety height.Its shape and size bone that can be used for filling various complicacy is damaged, and the solidification temperature of material is in a liquid state under the room temperature between 31 ~ 36 ℃, can be at self-curing under the body temperature, and hardening time was at 3 ~ 15 minutes; Can keep due shape in defect repair in cycle, possess excellent biological compatibility simultaneously, can promote the regeneration of bone.
Claims (10)
1. a medical slow release material mainly is to be mixed in the mixture that forms in the temperature sensitive type polymer solution by sustained-release micro-spheres; Said sustained-release micro-spheres is loaded with medicine, and forms the alternately microsphere of the pulsed slow release of release of identical or different medicine by the microsphere of different deenergized periods according to certain mixed together.
2. medical slow release material as claimed in claim 1; It is characterized in that: said temperature sensitive type polymer solution is a kind of injectable carrier solution; Mass concentration scope at room temperature is 1 ~ 20%, and this solution solidifies rapidly in 31 ~ 36 ℃ scope ability, forms solid gel; Said temperature sensitive type polymer solution is to be formed to dissolving fully by normal saline or phosphate buffer dissolving temperature sensitive type poly compound; Said temperature sensitive type poly compound is selected from a kind of in poly-N-isopropyl acrylamide, the grafted Polyethylene Glycol of poly-N-isopropyl acrylamide, the grafted chitosan of poly-N-isopropyl acrylamide, the grafted collagen of poly-N-isopropyl acrylamide, the grafted hyaluronic acid of poly-N-isopropyl acrylamide, the grafted chondroitin sulfate of poly-N-isopropyl acrylamide, the grafted sodium alginate of poly-N-isopropyl acrylamide and several kinds, and the molecular weight ranges of these polymer is at 0.5 ~ 5KDa.
3. medical slow release material as claimed in claim 1 is characterized in that: contained medicine is antibacterials and/or somatomedin; The content of medicine in microsphere accounts for 0.001% ~ 5% of microsphere gross mass; Said sustained-release micro-spheres mass and size specific concentration in mixture is 0.01 ~ 10%.
4. medical slow release material as claimed in claim 3 is characterized in that: said antibacterials are selected from one or more in streptomycin, cefradine, gentamycin, acetylspiramycin, erythromycin, albomycin, amoxicillin, oxytetracycline, kanamycin, penicillin, metronidazole, danshensu, neomycin, ribostamycin, tetracycline, vancomycin, the azithromycin; Said somatomedin is selected from one or more in rhBMP-2, rhBMP-7, insulin-like growth factor-i, transforming growth factor-beta, VEGF, basic fibroblast growth factor, platelet derived growth factor or the active polypeptide etc.
5. medical slow release material as claimed in claim 1 is characterized in that: the microsphere raw material is selected from one or more in polylactic acid, polyglycolic acid or the lactic acid-ethanol copolymer, and contains lactic acid-ethanol copolymer at least; The molecular weight ranges of microsphere raw material is 1~200KDa; The lactic acid-ethanol copolymer molecular weight is 1 ~ 3KDa in microsphere, and accounts for the microsphere gross mass and reach 30% when above, and microsphere can be regulated in 1 ~ 2 week deenergized period; When the lactic acid-ethanol copolymer molecular weight greater than 3 KDa and less than 10 KDa, and account for the microsphere gross mass and reach more than 50%, can regulate in 3 ~ 6 weeks deenergized period; When the lactic acid-ethanol copolymer molecular weight greater than 10KDa and less than 200 KDa, and the gross mass that accounts for microsphere is less than 50%, can regulate in 7 ~ 12 weeks deenergized period.
6. medical slow release material as claimed in claim 1; It is characterized in that: said pulsed discharges microsphere and comprises that be 5 kinds of microspheres in 1 week, 2 weeks, 4 weeks, 8 weeks and 12 weeks deenergized period, and mass ratio is (1 ~ 10): (1 ~ 10): (1 ~ 10): (1 ~ 10): (1 ~ 10); Be that the contained medicine of microsphere in 1 week and 2 weeks is antibacterials deenergized period; Be that the contained medicine of microsphere in 4 weeks, 8 weeks and 12 weeks is a somatomedin deenergized period.
7. like each described medical slow release material among the claim 1-6, it is the injection-type dosage form.
8. like each described medical slow release material among the claim 1-7, its preparation method may further comprise the steps:
1) pulsed of preparation medicine carrying thing discharges microsphere;
2) preparation temperature sensitive type polymer solution;
3) mixing: the medicine carrying pulsed of step 1) preparation is discharged microsphere and step 2) solution of preparation mixes, stirs, prepares the mixed solution of microsphere and polymer.
9. medical slow release preparation methods as claimed in claim 8 is characterized in that: further comprise step 4): solidifying, specifically is that the mixed solution of step 3 preparation is packed in the syringe, is expelled to therapentic part, and solidifies rapidly.
10. medical slow release preparation methods as claimed in claim 8 is characterized in that: the technology of said step 1) further comprises:
At first prepare the microsphere raw material of different deenergized periods and respectively with said medicine wiring solution-forming; Wherein the microsphere raw material is selected from one or more in polylactic acid, polyglycolic acid or the lactic acid-ethanol copolymer; And contain lactic acid-ethanol copolymer at least, the molecular weight ranges of microsphere raw material is 1~200KDa;
Produce the microsphere drop through the nebulizer atomizing; Obtain the different microsphere that is loaded with medicine deenergized period behind the volatile dry respectively: wherein; When the lactic acid-ethanol copolymer molecular weight is 1 ~ 3KDa, and accounts for the microsphere gross mass and reach 30% when above, obtain the microsphere that to regulate in 1 ~ 2 week deenergized period; When the lactic acid-ethanol copolymer molecular weight greater than 3 KDa and less than 10KDa, and account for the microsphere gross mass and reach more than 50%, obtain the microspheres that can regulate in 3 ~ 6 weeks deenergized period; When the lactic acid-ethanol copolymer molecular weight greater than 10KDa and less than 200KDa, and the gross mass that accounts for microsphere is less than 50%, obtains the microsphere that deenergized period can adjusting in 7 ~ 12 weeks;
Then, with the microspheres of different deenergized periods together, can form the microsphere of the pulsed slow release that identical or different medicine alternately discharges according to certain mixed.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110458810.8A CN102552994B (en) | 2011-12-31 | 2011-12-31 | Medical slow release material and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110458810.8A CN102552994B (en) | 2011-12-31 | 2011-12-31 | Medical slow release material and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102552994A true CN102552994A (en) | 2012-07-11 |
CN102552994B CN102552994B (en) | 2014-06-25 |
Family
ID=46400439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110458810.8A Expired - Fee Related CN102552994B (en) | 2011-12-31 | 2011-12-31 | Medical slow release material and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102552994B (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105664250A (en) * | 2016-01-27 | 2016-06-15 | 苏州佰通生物科技有限公司 | Injectable and degradable thermo-sensitive hydrogel and preparation method thereof |
CN106334184A (en) * | 2016-11-22 | 2017-01-18 | 吉林大学 | Ten-micron-scale multilayer core-shell sustained-release-microsphere preparation loading vascular endothelial growth factors and vancomycin and preparing method thereof |
CN108236731A (en) * | 2016-12-27 | 2018-07-03 | 中国科学院宁波材料技术与工程研究所 | A kind of sustained-release antibacterial dressing and preparation method thereof |
CN111214706A (en) * | 2018-11-25 | 2020-06-02 | 中国科学院大连化学物理研究所 | Temperature-sensitive composite gel emulsion and application thereof |
CN111265492A (en) * | 2020-04-17 | 2020-06-12 | 南京鼓楼医院 | Temperature-responsive drug-loaded microsphere with lubricating effect and preparation method thereof |
CN111494702A (en) * | 2020-05-08 | 2020-08-07 | 杭州口腔医院集团有限公司 | Antibacterial hydrogel and preparation method and application thereof |
CN113058074A (en) * | 2020-01-02 | 2021-07-02 | 华利源(上海)生物医药科技有限公司 | Temperature-sensitive filler composition |
CN113368304A (en) * | 2021-06-17 | 2021-09-10 | 福建师范大学 | Method for preparing multifunctional sodium alginate scaffold embedded with drug-loaded microspheres by using in-situ emulsification-based 3D printing technology |
CN113797384A (en) * | 2021-11-03 | 2021-12-17 | 浙江赛灵特医药科技有限公司 | Preparation method of injection type bone repair agent |
CN114617838A (en) * | 2022-02-16 | 2022-06-14 | 深圳高性能医疗器械国家研究院有限公司 | Drug delivery system and method for preparing same |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007022188A2 (en) * | 2005-08-15 | 2007-02-22 | New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery | A porous non-biodegradable hydrogel admixed with a chemoattractant for tissue replacement |
US20090111763A1 (en) * | 2007-10-26 | 2009-04-30 | Celonova Biosciences, Inc. | Loadable polymeric particles for bone augmentation and methods of preparing and using the same |
CN101612437A (en) * | 2009-01-09 | 2009-12-30 | 清华大学 | Naltrexone microsphere-hydrogel skeleton original position heeling-in drug-supplying system |
CN101816804A (en) * | 2010-02-05 | 2010-09-01 | 佘振定 | Injectable active bone repair material |
CN101934090A (en) * | 2010-08-25 | 2011-01-05 | 深圳清华大学研究院 | Injectable bone repairing material and preparation method thereof |
-
2011
- 2011-12-31 CN CN201110458810.8A patent/CN102552994B/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007022188A2 (en) * | 2005-08-15 | 2007-02-22 | New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery | A porous non-biodegradable hydrogel admixed with a chemoattractant for tissue replacement |
US20090111763A1 (en) * | 2007-10-26 | 2009-04-30 | Celonova Biosciences, Inc. | Loadable polymeric particles for bone augmentation and methods of preparing and using the same |
CN101612437A (en) * | 2009-01-09 | 2009-12-30 | 清华大学 | Naltrexone microsphere-hydrogel skeleton original position heeling-in drug-supplying system |
CN101816804A (en) * | 2010-02-05 | 2010-09-01 | 佘振定 | Injectable active bone repair material |
CN101934090A (en) * | 2010-08-25 | 2011-01-05 | 深圳清华大学研究院 | Injectable bone repairing material and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
曾魁等: "卵清蛋白-PLGA抗原微球脉冲释放体系的研究", 《广东化工》, vol. 38, no. 11, 25 November 2011 (2011-11-25), pages 10 - 11 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105664250A (en) * | 2016-01-27 | 2016-06-15 | 苏州佰通生物科技有限公司 | Injectable and degradable thermo-sensitive hydrogel and preparation method thereof |
CN106334184A (en) * | 2016-11-22 | 2017-01-18 | 吉林大学 | Ten-micron-scale multilayer core-shell sustained-release-microsphere preparation loading vascular endothelial growth factors and vancomycin and preparing method thereof |
CN108236731A (en) * | 2016-12-27 | 2018-07-03 | 中国科学院宁波材料技术与工程研究所 | A kind of sustained-release antibacterial dressing and preparation method thereof |
CN111214706A (en) * | 2018-11-25 | 2020-06-02 | 中国科学院大连化学物理研究所 | Temperature-sensitive composite gel emulsion and application thereof |
CN113058074A (en) * | 2020-01-02 | 2021-07-02 | 华利源(上海)生物医药科技有限公司 | Temperature-sensitive filler composition |
CN113058074B (en) * | 2020-01-02 | 2022-04-29 | 华利源(上海)生物医药科技有限公司 | Temperature-sensitive filler composition |
CN111265492A (en) * | 2020-04-17 | 2020-06-12 | 南京鼓楼医院 | Temperature-responsive drug-loaded microsphere with lubricating effect and preparation method thereof |
CN111494702A (en) * | 2020-05-08 | 2020-08-07 | 杭州口腔医院集团有限公司 | Antibacterial hydrogel and preparation method and application thereof |
CN111494702B (en) * | 2020-05-08 | 2021-09-17 | 杭州口腔医院集团有限公司 | Antibacterial hydrogel and preparation method and application thereof |
CN113368304A (en) * | 2021-06-17 | 2021-09-10 | 福建师范大学 | Method for preparing multifunctional sodium alginate scaffold embedded with drug-loaded microspheres by using in-situ emulsification-based 3D printing technology |
CN113368304B (en) * | 2021-06-17 | 2022-02-15 | 福建师范大学 | Method for preparing multifunctional sodium alginate scaffold embedded with drug-loaded microspheres by using in-situ emulsification-based 3D printing technology |
CN113797384A (en) * | 2021-11-03 | 2021-12-17 | 浙江赛灵特医药科技有限公司 | Preparation method of injection type bone repair agent |
CN113797384B (en) * | 2021-11-03 | 2022-10-21 | 浙江赛灵特医药科技有限公司 | Preparation method of injection type bone repair agent |
CN114617838A (en) * | 2022-02-16 | 2022-06-14 | 深圳高性能医疗器械国家研究院有限公司 | Drug delivery system and method for preparing same |
Also Published As
Publication number | Publication date |
---|---|
CN102552994B (en) | 2014-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102552994B (en) | Medical slow release material and preparation method thereof | |
JP5923493B2 (en) | Method for preparing an injectable depot composition | |
DE69533404T2 (en) | DIFFERENTIALLY BIOABBAUBABLE MEDICAL INPLANTS | |
JP5319278B2 (en) | Bioresorbable polymer matrix and methods of making and using the same | |
JP5882993B2 (en) | Antipsychotic depot injection composition | |
JP6324653B2 (en) | Minimally invasive treatment of vertebrae using bone cement containing bone cement (MITV) | |
US5945115A (en) | Polymeric compositions useful as controlled release implants | |
US10363238B2 (en) | Methods and compositions to enhance bone growth comprising a statin | |
JP6248068B2 (en) | Compositions and methods for callus extension | |
JP2007533376A (en) | Delayed solidification calcium phosphate paste | |
KR20130058762A (en) | Platelet-derived growth factor compositions and methods of use thereof | |
JP2013527213A5 (en) | ||
WO2007147014A2 (en) | Method and systems for using biopolymer-based beads and hydrogels | |
US20080175911A1 (en) | Compositions and methods for soft tissue repair | |
JP2003530363A (en) | Injectable bone mineral replacement material | |
JPH11506659A (en) | Biocompatible hydroxyapatite formulations and uses thereof | |
CN103877621B (en) | Electrospun fiber-reinforced calcium phosphate bone cement composite material and application thereof | |
CN108273131A (en) | A kind of composite bone cement, preparation method and applications and a kind of bone renovating material | |
JP2022068212A (en) | Scaffold material, methods, and uses | |
CN102858278B (en) | Flowable ceramic putty | |
CN104645418A (en) | Injectable bone cement and preparation method thereof | |
CN102872450A (en) | Composition for composite drug administration | |
KR101959523B1 (en) | Composition comprising nucleic acids, bone graft materials and cationic polymers for bone grafting and kit for manufacturing the same | |
CN110498664A (en) | A kind of preparation method of the multiphase calcium orthophosphate base bone cement of high intensity injectable | |
Carrêlo et al. | Injectable Composite Systems Based on Microparticles in Hydrogels for Bioactive Cargo Controlled Delivery. Gels 2021, 7, 147 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140625 |
|
CF01 | Termination of patent right due to non-payment of annual fee |